This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ARNA Arena Pharmaceuticals (ARNA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Arena Pharmaceuticals Stock (NASDAQ:ARNA) 30 days 90 days 365 days Advanced Chart Get Arena Pharmaceuticals alerts:Sign Up Key Stats Today's Range$99.99▼$99.9950-Day Range$93.13▼$99.9952-Week Range$45.50▼$100.00Volume107 shsAverage Volume1.56 million shsMarket Capitalization$6.17 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc. Read More Receive ARNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARNA Stock News HeadlinesNeuvivo makes bid to enter ALS arena with immunotherapy candidateOctober 7, 2024 | msn.comArwana Citramulia Tbk (ARNA)August 31, 2023 | uk.investing.comBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most investors are still asleep… but not for long. Garrett Goggin’s latest research reveals how you can “front-run” the greatest investor alive by positioning in four small miners sitting on up to 100X potential upside. When this hits the news — it’ll be too late.July 12 at 2:00 AM | Golden Portfolio (Ad)MLS club places Bruce Arena on leave over probe into 'allegations of insensitive and inappropriate remarks'August 21, 2023 | foxnews.comRNA startup launches with $300M, Merck partnershipMay 23, 2023 | bizjournals.comLongboard Pharmaceuticals: Undervalued Arena Spin-Out Has 2 Data Catalysts Due In 2023May 23, 2023 | seekingalpha.comPfizer earnings and revenue top expectations despite Covid vaccine sales declineMay 6, 2023 | cnbc.comArna L. DavidsonApril 25, 2023 | health.usnews.comSee More Headlines ARNA Stock Analysis - Frequently Asked Questions How were Arena Pharmaceuticals' earnings last quarter? Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) earnings per share for the quarter, missing the consensus estimate of ($2.53) by $0.68. When did Arena Pharmaceuticals' stock split? Arena Pharmaceuticals's stock reverse split on the morning of Monday, June 19th 2017.The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Arena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Meta Platforms (META), Cytokinetics (CYTK), Micron Technology (MU), Bristol Myers Squibb (BMY) and Canopy Growth (CGC). Company Calendar Last Earnings11/04/2021Today7/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ARNA CIK1080709 Webwww.arenapharm.com Phone(858) 453-7200Fax858-453-7210Employees448Year Founded1977Profitability EPS (Trailing Twelve Months)($10.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$616.43 million Net MarginsN/A Pretax Margin-1,141,542.63% Return on Equity-69.83% Return on Assets-62.35% Debt Debt-to-Equity Ratio0.05 Current Ratio8.59 Quick Ratio8.59 Sales & Book Value Annual Sales$50 thousand Price / Sales123,305.67 Cash FlowN/A Price / Cash FlowN/A Book Value$10.94 per share Price / Book9.14Miscellaneous Outstanding Shares61,659,000Free Float60,173,000Market Cap$6.17 billion OptionableOptionable Beta0.55 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ARNA) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arena Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arena Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.